user

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective

被引：6
|
作者：
Harbeck, Nadia [1 ]
Marschner, Norbert [2 ]
Untch, Michael [3 ]
Decker, Thomas [4 ]
Hegewisch-Becker, Susanna [5 ]
Jackisch, Christian [6 ]
Huober, Jens [7 ]
Lueck, Hans-Joachim [8 ]
von Minckwitz, Gunter [9 ]
Scharl, Anton [10 ]
Schneeweiss, Andreas [11 ]
Tesch, Hans [12 ]
Welt, Anja [13 ]
Wuerstlein, Rachel [14 ]
Thomssen, Christoph [15 ]
机构：
[1] Univ Munich, Frauenklin, Brustzentrum, D-81377 Munich, Germany
[2] Gemeinschaftspraxis Interdisziplinare Onkol & Ham, Freiburg, Germany
[3] HELIOS Klinikum Berlin Buch, Klin Gynakol, Berlin, Germany
[4] Gemeinschaftspraxis Onkol Ravensburg, Ravensburg, Germany
[5] Onkol Schwerpunktpraxis Eppendorf, Hamburg, Germany
[6] Sana Klinikum Offenbach, Klin Gynakol & Geburtshilfe, Offenbach, Germany
[7] Univ Frauenklin Ulm, Ulm, Germany
[8] Gynakol Onkol Praxis Hannover, Hannover, Germany
[9] Univ Frauenklin Frankfurt, GBG Forsch GmbH Neu Isenburg, Neu Isenburg Frankfurt, Germany
[10] Frauenklinikum Klinikums St Marien, Amberg, Germany
[11] Natl Zentrum Tumorerkrankungen, Sekt Gynakol Onkol, Heidelberg, Germany
[12] Onkol Gemeinschaftspraxis Frankfurt, Frankfurt, Germany
[13] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Innere Klin Tumorforsch, Essen, Germany
[14] Klinikum Univ Munchen, Brustzentrum, Frauenklin, Munich, Germany
[15] Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, D-06108 Halle, Germany
来源：
BREAST CARE | 2014年 / 9卷 / 01期
关键词：
Locally advanced breast cancer; LABC; Metastatic breast cancer; MBC; Consensus; AGO;
D O I：
10.1159/000358689
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Advanced Breast Cancer Second International Consensus Conference (ABC2) on diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, on November 7-9, 2013. The focus of the conference was inoperable, locally advanced breast cancer. The diagnosis and treatment of metastatic breast cancer had already been discussed 2 years before at the ABC1 Consensus and were only updated regarding special issues as part of this year's ABC2 Consensus. Like 2 years ago, a working group of German breast cancer experts commented on the voting results of the ABC panelists, with special consideration of the German guidelines for the diagnosis and treatment of breast cancer (German Gynecological Oncology Working Group (AGO) recommendations, S3 Guideline) in order to adapt them for daily clinical practice in Germany. The goal of both the ABC Consensus and the German comments is to facilitate evidence-based therapy decisions.
引用
收藏
页码：52 / 59
页数：8
相关论文
共 50 条
  • [41] MONARCH 2: subgroup analysis of patients receiving abema-ciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer (ABC)
    Neven, P.
    Johnston, S.
    Toi, M.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Koh, H.
    Grischke, E. -M.
    Conte, P.
    Lu, Y.
    Haddad, N.
    Hurt, K.
    Kaufman, P. A.
    Llombart Cussac, A.
    Sledge, G. W., Jr.
    Bodmer, A.
    [J]. SWISS MEDICAL WEEKLY, 2020, : 8S - 8S
  • [42] Real-world data of Advanced Breast Cancer (ABC) patients with HER2-positivity before the second-line therapy: data from the observational study GEICAM/2014-03 (RegistEM)
    Lopez-Tarruella, Sara
    Guerrero-Zotano, Angel
    Cruz, Josefina
    Novoa, Silvia Antolin
    Martinez, Purificacion
    Hernandez, Maria
    Rodriguez, Cesar A.
    Chacon, J. Ignacio
    Tibau, Ariadna
    Falo, Catalina
    Rodriguez-Lescure, Alvaro
    Margeli, Mireia
    Servitja, Sonia
    Andres, Raquel
    Galan-Gramaje, Maria
    Adrover, Encarna
    Miguel, Ana
    Villanueva, Rafael
    Varela, Silvia
    Campo, Ruth
    Escudero, Ma Jose
    Bezares, Susana
    Rojo, Federico
    Alvarez, Isabel
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [43] Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Wang, Yingcheng
    Rui, Mingjun
    Guan, Xin
    Cao, Yingdan
    Chen, Pingyu
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [44] Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2-advanced breast cancer-A Chinese healthcare system perspective
    Zhu, Wentao
    Zheng, Miaomiao
    Xia, Panpan
    Hong, Wanglong
    Ma, Guoqiang
    Shen, Aizong
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    [J]. VALUE IN HEALTH, 2020, 23 : S39 - S39
  • [46] Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2-advanced or metastatic breast cancer: a US payer perspective
    Zeng, Wanxian
    Cao, Xueqiong
    Lin, Jingwen
    Zheng, Bin
    Li, Na
    Liu, Maobai
    Cai, Hongfu
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP)
    Gallagher, Emily J.
    Moore, Heather
    Lacouture, Mario E.
    Dent, Susan Faye
    Farooki, Azeez
    Goncalves, Marcus D.
    Isaacs, Claudine
    Johnston, Abigail
    Juric, Dejan
    Quandt, Zoe
    Spring, Laura
    Berman, Brian
    Decker, Melanie
    Hortobagyi, Gabriel N.
    Kaffenberger, Benjamin
    Kwong, Bernice Y.
    Pluard, Timothy J.
    Rao, Ruta D.
    Schwartzberg, Lee S.
    Broder, Michael S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 422 - 422
  • [48] Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[ plus ])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
    Llombart-Cussac, Antonio
    Harper-Wynne, Catherine
    Perello, Antonia
    Hennequin, Audrey
    Fernandez, Adela
    Colleoni, Marco
    Caranana, Vicente
    Quiroga, Vanesa
    Medioni, Jacques
    Iranzo, Vega
    Wheatley, Duncan
    Del Barco, Sonia
    Anton, Antonio
    Dobi, Erion
    Ruiz-Borrego, Manuel
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R plus F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    [J]. VALUE IN HEALTH, 2020, 23 : S45 - S45
  • [50] Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)
    Fasching, P.
    Neven, P.
    Jerusalem, G.
    Beck, J. T.
    Chan, A.
    De Laurentiis, M.
    Bianchi, G. V.
    Martin Jimenez, M.
    Chia, S.
    Gaur, A.
    Sondhi, M.
    Rodriguez-Lorenc, K.
    Lanoue, B.
    Chandiwana, D.
    Nusch, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S67 - S68
12345